Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 23, 2023 - Issue 2
Submit an article Journal homepage
2,581
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study

Charles V. Pollack Jra Emergency Medicine, University of Mississippi, Jackson, Mississippi, United StatesView further author information
,
Abiy Agirob US Medical Affairs, AstraZeneca, Wilmington, Delaware, United StatesCorrespondence[email protected]
View further author information
,
Fan Muc Health Economics and Outcomes Research, Analysis Group, Boston, MassachusettsView further author information
,
Erin E. Cookc Health Economics and Outcomes Research, Analysis Group, Boston, MassachusettsORCID Iconhttps://orcid.org/0000-0001-9737-9130View further author information
ORCID Icon,
Esteban Lemus Wirtzc Health Economics and Outcomes Research, Analysis Group, Boston, MassachusettsView further author information
,
Joshua A. Youngc Health Economics and Outcomes Research, Analysis Group, Boston, MassachusettsView further author information
,
Keith A. Bettsc Health Economics and Outcomes Research, Analysis Group, Boston, MassachusettsView further author information
&
Yasmin G. Brahmbhattb US Medical Affairs, AstraZeneca, Wilmington, Delaware, United StatesView further author information
 show all
Pages 241-250 | Received 17 Jun 2022, Accepted 19 Dec 2022, Published online: 28 Dec 2022

References

  • Fried L, Kovesdy CP, Palmer BF. New options for the management of chronic hyperkalemia. Kidney Int Suppl. 2017;7:164–170.
  • Montford JR, Linas S. How dangerous is hyperkalemia? J Am Soc Nephrol. 2017;28:3155–3165.
  • Betts KA, Woolley JM, Mu F, et al. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3:385–393.
  • Desai NR, Reed P, Alvarez PJ, et al. The economic implications of hyperkalemia in a medicaid managed care population. Am Health Drug Benefits. 2019;12:352–361.
  • Betts KA, Woolley JM, Mu F, et al. Postdischarge health care costs and readmission in patients with hyperkalemia-related hospitalizations. Kidney Int Rep. 2020;5:1280–1290.
  • Fitch K, Woolley JM, Engel T, et al. The clinical and economic burden of hyperkalemia on medicare and commercial payers. Am Health Drug Benefits. 2017;10:202–210.
  • Mu F, Betts KA, Woolley JM, et al. Prevalence and economic burden of hyperkalemia in the United States medicare population. Curr Med Res Opin. 2020;36:1333–1341.
  • Dashputre AA, Gatwood J, Sumida K, et al. Association of dyskalemias with short-term health care utilization in patients with advanced CKD. J Manag Care Spec Pharm. 2021;27:1403–1415.
  • Sharma A, Alvarez PJ, Woods SD, et al. Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population. J Pharm Health Serv Res. 2021;12:35–41.
  • Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96:744–762.
  • Palmer BF. Potassium binders for hyperkalemia in chronic kidney disease-diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. Mayo Clin Proc. 2020;95:339–354.
  • Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10:653–662.
  • Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the working group on cardiovascular pharmacotherapy of the European society of cardiology. Eur Heart J Cardiovasc Pharmacother. 2018;4:180–188.
  • Laureati P, Xu Y, Trevisan M, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2020;35:1518–1526.
  • Rahman S, Marathi R. Sodium polystyrene sulfonate. StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
  • Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:S1–S87.
  • Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e876–94.
  • AstraZeneca. Lokelma US label updated to include dosing guidance for the treatment of hyperkalaemia in patients with end-stage renal disease on haemodialysis. 2020. [cited 2022 Feb 10]. Available from: https://www.astrazeneca.com/content/astraz/media-centre/medical-releases/lokelma-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis.html.
  • Desai NR, Alvarez PJ, Golestaneh L, et al. Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients. J Med Econ. 2021;24:1025–1036.
  • Kovesdy CP, Gosmanova EO, Woods SD, et al. Real-world management of hyperkalemia with patiromer among United States veterans. Postgrad Med. 2020;132:176–183.
  • Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312:2223–2233.
  • Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month Phase 3 study. Clin J Am Soc Nephrol. 2019;14:798–809.
  • Cohen MJ, Shaykevich S, Cawthon C, et al. Predictors of medication adherence postdischarge: the impact of patient age, insurance status, and prior adherence. J Hosp Med. 2012;7:470–475.
  • Gasparini A, Evans M, Barany P, et al. Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Nephrol Dial Transplant. 2019;34:1534–1541.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.